The present invention relates to interferon-gamma (IFN-γ) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-γ production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof； (I), (II), (III) in which: A is an aromatic ring selected from； i. a phenyl ring substituted with up to five substituents, each independently selected from halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, and haloalkoxy groups having from 1 to 4 carbon atoms； ii. a thiophene ring optionally substituted with up to three substituents each selected independently from halogen atoms, alkyl groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms and haloalkoxy groups having from 1 to 4 carbon atoms； and iii. a C(Rd)3 group, wherein each Rd is independently selected from hydrogen, alkyl groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, haloalkoxy groups having from 1 to 4 carbon atoms, and phenyl rings optionally substituted with up to five substituents, each independently selected from halogen atoms, alkyl groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, and haloalkoxy groups having from 1 to 4 carbon atoms, cycloalkyl groups having from 3 to 8 carbon atoms, halocycloalkyl groups having from 3 to 8 carbon atoms, and wherein at least one Rd is an optionally substituted phenyl ring； Ra is selected from hydrogen, haloalkyl gro
